EDISON values SYGNIS at 37.5 million euros

12-Jul-2013 - Germany

EDISON published a thorough analysis of SYGNIS Pharma AG . As a result of EDISON’s analysis of the company, the objective value of SYGNIS, taking into account the launch of QualiPhi in the third quarter of 2013 – licensed by Qiagen – as well as the license of two further products this year: PrimPol and Double Switch, would reach 37.5 million euros.  

In order to undertake the analysis of the share value of SYGNIS, EDISON focused on the predicted income of three products: QualiPhi, PrimPol and Double Switch. Meanwhile, EDISON have not considered any additional products the company has been developing (DNA repair kit). 

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance